Vontobel Holding Ltd. Sells 30,000 Shares of Chimerix, Inc. (NASDAQ:CMRX)

Vontobel Holding Ltd. cut its position in Chimerix, Inc. (NASDAQ:CMRX) by 42.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 40,000 shares of the biopharmaceutical company’s stock after selling 30,000 shares during the quarter. Vontobel Holding Ltd.’s holdings in Chimerix were worth $139,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Assenagon Asset Management S.A. raised its stake in shares of Chimerix by 154.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company’s stock valued at $2,846,000 after purchasing an additional 496,823 shares during the period. Peapod Lane Capital LLC bought a new stake in shares of Chimerix during the 4th quarter valued at $2,626,000. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Chimerix by 66.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock valued at $321,000 after purchasing an additional 138,098 shares during the period. Finally, Stoneridge Investment Partners LLC raised its stake in shares of Chimerix by 22.5% during the 4th quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company’s stock valued at $154,000 after purchasing an additional 8,134 shares during the period. 45.42% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CEO Michael T. Andriole sold 7,370 shares of the business’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $4.52, for a total transaction of $33,312.40. Following the completion of the transaction, the chief executive officer now directly owns 609,603 shares in the company, valued at $2,755,405.56. The trade was a 1.19 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 20,760 shares of company stock worth $91,175 over the last ninety days. 13.10% of the stock is owned by corporate insiders.

Chimerix Stock Down 0.1 %

Chimerix stock opened at $5.16 on Friday. Chimerix, Inc. has a 52 week low of $0.75 and a 52 week high of $5.53. The business has a 50-day simple moving average of $3.77 and a 200 day simple moving average of $1.95. The stock has a market cap of $464.45 million, a price-to-earnings ratio of -5.49 and a beta of 0.35.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $11.00 price objective on shares of Chimerix in a research note on Tuesday. Wedbush restated an “outperform” rating and set a $7.00 target price (up from $6.00) on shares of Chimerix in a research report on Tuesday.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.